Remdesivir improves biomarkers associated with disease severity in COVID-19 patients treated in an outpatient setting
oleh: David Z. Pan, Pamela M. Odorizzi, Andre Schoenichen, Mazin Abdelghany, Shuguang Chen, Anu Osinusi, Scott D. Patterson, Bryan Downie, Kavita Juneja, Jeffrey J. Wallin
| Format: | Article |
|---|---|
| Diterbitkan: | Nature Portfolio 2023-01-01 |
Deskripsi
Pan et al. determine the impact of the antiviral remdesivir (RDV) on biomarkers associated with clinical outcomes, within a randomized, double-blind, placebo-controlled phase 3 study (PINETREE). They demonstrate that RDV-treated patients have an accelerated reduction in soluble angiopoietin-2, D-dimer and neutrophil-to-lymphocyte ratios.